Key result
AI-derived pleural effusion volume fails to predict long-term mortality after TAVI.
Why the study?
Pleural effusions are common on pre-procedural CT in TAVI patients, but their clinical and prognostic significance in contemporary cohorts remains poorly understood.
Does AI-derived pleural effusion volume predict long-term mortality in patients undergoing TAVI?
Cohort (n=470)
No
Does AI-derived pleural effusion volume predict long-term mortality in patients undergoing TAVI?
Hazard Ratio: 1 (95% CI 0.93–1.08)
p-value: p=0.976
AI-derived pleural effusion volume reflects cardiovascular congestion and hemodynamic impairment in TAVI patients but does not independently predict long-term mortality.
AI pleural effusion quantification should not guide TAVI risk stratification; leaves open its value for congestion phenotyping in prospective cohorts.
Background/Objectives: Pleural effusions are frequently encountered on pre-procedural computed tomography (CT) scans in patients undergoing transcatheter aortic valve implantation (TAVI). While often regarded as a marker of congestion and advanced cardiovascular disease, their clinical and prognostic significance in contemporary TAVI populations remains poorly understood. This study investigated the relationship between AI-derived pleural effusion volume, cardiovascular dysfunction, and long-term mortality after TAVI. Methods: Consecutive patients undergoing transfemoral TAVI between 2016 and 2022 who had available pre-procedural CT imaging were retrospectively included. Pleural effusion volume was quantified using an artificial intelligence-based segmentation workflow and analyzed as categorical, continuous, log-transformed, and threshold-based variables. Associations with clinical and echocardiographic characteristics were evaluated using Spearman correlation analyses. Long-term mortality was assessed using Kaplan–Meier analysis, Cox proportional hazards regression, and restricted cubic spline models. Results: A total of 470 patients were included (median age 82 years, 50.9% male). Pleural effusion was present in 124 patients (26.38%), including 73 (15.53%) with small, 26 (5.53%) with moderate, and 25 (5.32%) with larger effusions. Increasing pleural effusion volume was associated with atrial fibrillation (AF) (rho = 0.189, p < 0.001), higher systolic pulmonary artery pressure (rho = 0.224, p < 0.001), lower tricuspid annular plane systolic excursion (rho = −0.236, p < 0.001), impaired right ventricular–pulmonary arterial coupling (rho = −0.267, p < 0.001), lower stroke volume index (rho = −0.229, p < 0.001), and reduced left ventricular ejection fraction (rho = −0.221, p < 0.001). Despite these associations, pleural effusion volume was not associated with long-term mortality in univariable analyses, multivariable Cox regression models, or restricted cubic spline analyses. In the fully adjusted model, log-transformed pleural effusion volume was not independently associated with mortality (HR 1.00, 95% CI 0.93–1.08; p = 0.976). Conclusions: AI-derived pleural effusion volume is associated with markers of cardiovascular congestion and adverse hemodynamic remodeling in patients undergoing TAVI. However, pleural effusion burden does not independently predict long-term mortality, suggesting that its value lies primarily in phenotyping cardiovascular disease severity rather than risk stratification.
No takes yet. Share an insight, caveat, or question.
Schörghofer et al. (2026) conducted a cohort in Severe symptomatic aortic stenosis (n=470). AI-derived pleural effusion volume vs. No pleural effusion or lower pleural effusion volume was evaluated on All-cause mortality (HR 1.00, 95% CI 0.93-1.08, p=0.976). AI-derived pleural effusion volume was associated with markers of cardiovascular congestion but did not independently predict long-term mortality after TAVI (HR 1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: